Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Therapeutics and Diagnostics for Women's Disorders
Market Study
Published: March 2009
Pages: 195
Tables: 44
From: GBP 3031.00 Buy Now!
Research from: Business Communications Company Inc.
Sector: Indications Areas
The Report:
The U.S. market for therapeutics and diagnostics for women’s disorders was worth $29.9 billion in 2008. This should increase to $50.0 billion in 2013, for a compound annual growth rate (CAGR) of 10.9%.
The rheumatoid arthritis and osteoporosis segment has the largest share of the market, generating $10.6 billion in 2008. This is expected to grow at a CAGR of 11.5% to reach $18.2 billion in 2013.
Reproductive related therapies and diagnostics currently have the second largest market share, worth $5.9 billion in 2008. This should reach $7.5 billion in 2013, for a CAGR of 5.0%. INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC Research report, Therapeutics and Diagnostics for Women’s Disorders, provides an overview of products included in this market, and detailed analyses of markets and competitive environments. The study includes information about significant products, players, issues and trends, and other information affecting the women’s disorders and diseases industry.
REASONS FOR DOIING THE STUDY
New therapeutics and diagnostics have emerged in the last few years that have had a significant impact on women’s health. This study updates the previous BCC New Therapeutics and Diagnostics for Women’s Disorders with what has been happening in this arena since 2005.
This area covers a wide variety of products and disorders that affect predominantly women. Ongoing patient management studies will increase the number of indications. Keeping in touch with these applications for the various products is good business practice. This study will provide the reader with the knowledge to adequately view and assess the women’s healthcare movement and provide insights into the market potentials.
SCOPE OF REPORT
This newly updated BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the market for women’s therapeutic and diagnostic products. The geographical scope of this study is U.S. based. The report identifies markets in general segments:
Autoimmune diseases
Women’s cancer
Gynecological diseases and infections
Kidney and urological diseases and infections
Reproductive-related therapies and diagnostics
Rheumatoid arthritis and osteoporosis
Each market segment provides detailed information based on product categories, use of products, forecasts, and competitive analyses.
METHODOLOGY
The information for this BCC Research report was obtained through primary and secondary data collection methods. Primary methods included interviews with more than 50 key executives, product managers, clinical specialists and other related key personnel involved in the women’s healthcare industry. Secondary sources included published literature, investment reports, company literature, and various business journals that have emphasis on women’s health and related areas.
Market data for this report pertains to the U.S. market and uses U.S. dollars at the manufacturers’ level. The base year of the report is 2008, with historical data provided for 2006 and 2007, and forecast data provided for 2013. Historical, base year and forecast data are provided for each market segment of the report. Growth rates are determined through a compilation of data including past trends, future trends, demographics, incidence, mortality, products in research and development, and current product growth, etc. Competitor market share estimates are provided for each market segment for the 2008 base year.
The U.S. market for therapeutics and diagnostics for women’s disorders was worth $29.9 billion in 2008. This should increase to $50.0 billion in 2013, for a compound annual growth rate (CAGR) of 10.9%.
The rheumatoid arthritis and osteoporosis segment has the largest share of the market, generating $10.6 billion in 2008. This is expected to grow at a CAGR of 11.5% to reach $18.2 billion in 2013.
Reproductive related therapies and diagnostics currently have the second largest market share, worth $5.9 billion in 2008. This should reach $7.5 billion in 2013, for a CAGR of 5.0%. INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC Research report, Therapeutics and Diagnostics for Women’s Disorders, provides an overview of products included in this market, and detailed analyses of markets and competitive environments. The study includes information about significant products, players, issues and trends, and other information affecting the women’s disorders and diseases industry.
REASONS FOR DOIING THE STUDY
New therapeutics and diagnostics have emerged in the last few years that have had a significant impact on women’s health. This study updates the previous BCC New Therapeutics and Diagnostics for Women’s Disorders with what has been happening in this arena since 2005.
This area covers a wide variety of products and disorders that affect predominantly women. Ongoing patient management studies will increase the number of indications. Keeping in touch with these applications for the various products is good business practice. This study will provide the reader with the knowledge to adequately view and assess the women’s healthcare movement and provide insights into the market potentials.
SCOPE OF REPORT
This newly updated BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the market for women’s therapeutic and diagnostic products. The geographical scope of this study is U.S. based. The report identifies markets in general segments:
Autoimmune diseases
Women’s cancer
Gynecological diseases and infections
Kidney and urological diseases and infections
Reproductive-related therapies and diagnostics
Rheumatoid arthritis and osteoporosis
Each market segment provides detailed information based on product categories, use of products, forecasts, and competitive analyses.
METHODOLOGY
The information for this BCC Research report was obtained through primary and secondary data collection methods. Primary methods included interviews with more than 50 key executives, product managers, clinical specialists and other related key personnel involved in the women’s healthcare industry. Secondary sources included published literature, investment reports, company literature, and various business journals that have emphasis on women’s health and related areas.
Market data for this report pertains to the U.S. market and uses U.S. dollars at the manufacturers’ level. The base year of the report is 2008, with historical data provided for 2006 and 2007, and forecast data provided for 2013. Historical, base year and forecast data are provided for each market segment of the report. Growth rates are determined through a compilation of data including past trends, future trends, demographics, incidence, mortality, products in research and development, and current product growth, etc. Competitor market share estimates are provided for each market segment for the 2008 base year.